Mark Vincent

11.0k citations
171 papers · 6.5k · 2 hit papers · h-index 38

Impact in

  • Oncology top 0.5%
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
    • Occupational and environmental lung diseases
    • Pleural and Pulmonary Diseases
    • Gastric Cancer Management and Outcomes

Papers in

    • Colorectal Cancer Treatments and Studies 42
    • Lung Cancer Research Studies 31
    • Cancer Treatment and Pharmacology 19
    • Lung Cancer Treatments and Mutations 43
    • Lung Cancer Diagnosis and Treatment 26
    • Gastric Cancer Management and Outcomes 18

Mark Vincent

165 papers receiving 6.3k citations

Mark Vincent's Hit Papers

Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada 2005 · 474 citations
4740+8+17Years since publication50010001.5k

Peers

Mark Vincent
Comparison fields: 5 of 138
  • Oncology 3.8k
  • Pulmonary and Respiratory Medicine 3.7k
  • Cancer Research 723
  • Hepatology 206
  • Molecular Biology 1.5k
Replace Petr Zatloukal with:
Petr Zatloukal Czechia
Philip Bonomi United States
George R. Simon United States
Ikuo Sekine Japan
Alan B. Sandler United States
Stephen L. Graziano United States
Thomas E. Stinchcombe United States
Jyoti D. Patel United States
Nagio Takigawa Japan
K. Mattson Finland
Mark Vincent relative to Petr Zatloukal Czechia Petr Zatloukal's profile →
Citations per field
00.5×1.5×1.9×
Petr Zatloukal · 1×
Citations per year

Countries citing papers authored by Mark Vincent

Since Specialization
Citations

This map shows the geographic impact of Mark Vincent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Vincent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Vincent more than expected).

Fields of papers citing papers by Mark Vincent

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Vincent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Vincent. The network helps show where Mark Vincent may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Vincent, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Vincent Line = papers co-authored together Mark Vincent links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 171 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Hit paper breakdown →
20001717
2
Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
Hit paper breakdown →
2005474
3 2009295
4 2002249
5 2009186
6 2003181
7 2017138
8 2014132
9 2007109
10 200194
11 201092
12 200588
13 198783
14
Prolonged remission of severe refractory rheumatoid arthritis following allogeneic bone marrow transplantation for drug-induced aplastic anaemia.
198682
15 200581
16 201178
17 199871
18 201168
19 198765
20 201465

About Mark Vincent

Mark Vincent is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Surgery and Cancer Research, having authored 171 papers that have together received 6.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (43 papers), Colorectal Cancer Treatments and Studies (42 papers), Lung Cancer Research Studies (31 papers), Lung Cancer Diagnosis and Treatment (26 papers), Cancer Treatment and Pharmacology (19 papers), Gastric Cancer Management and Outcomes (18 papers), Cancer Genomics and Diagnostics (14 papers) and Genetic factors in colorectal cancer (11 papers). The work is most often cited by research in Oncology (3.8k citations), Pulmonary and Respiratory Medicine (3.7k citations), Cancer Research (723 citations), Hepatology (206 citations) and Molecular Biology (1.5k citations). Mark Vincent has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Frances A. Shepherd, Ronald L. Burkes, Janet Dancey, J. Bérille, Rodryg Ramlau, Laurent Gressot, K. Mattson, Susan Coughlin, Nathan Levitan and Yong Kim. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, Lung Cancer, European Journal of Cancer and Journal of Thoracic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact